Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma

• Status: Unknown status
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is a local, prospective, non-interventional, non-controlled, multicenter, observational study (regulatory postmarketing surveillance). Each physician will enroll patients who have received at least 1 dose of Yervoy, and each patient will be followed for up to 12 months. All patients will be evaluated for safety and effectiveness during Yervoy use (4 doses) and for 12 months from the first dose of Yervoy to confirm the safety profile of Yervoy under routine, daily practice

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Ono Pharmaceutical Co. Ltd
• Treatments: Ipilimumab

Criteria

Inclusion Criteria:

• All patients who are initiating treatment with Yervoy

Exclusion Criteria:

• Not Applicable

Other protocol defined inclusion/exclusion criteria could apply